Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
UNLV Office of Technology Transfer and Economic Development
UNLV is Nevada’s premier public research university and a powerhouse for groundbreaking discovery and innovation, particularly in life sciences and biotechnology. At the forefront of UNLV’s industry and business engagement are our dynamic offices of Economic Development and Technology Transfer, serving as vital connectors between pioneering research and impactful commercialization opportunities. UNLV’s cutting-edge Brain Health Department as well as the innovative Wastewater Surveillance Laboratory exemplify our bold approach to solving complex health and environmental challenges. Researchers at these centers drive groundbreaking advancements with profound implications for neuroscience, public health, environmental monitoring, and disease prevention. Uniquely situated within a collaborative and vibrant regional ecosystem, UNLV thrives alongside major stakeholders committed to ambitious, strategic coordination and innovative thinking. This environment enables business and industry partnerships to flourish, supported by open communication and outside-the-box planning that accelerate shared success. At BIO International 2025, our goal is clear: to connect industry leaders, visionaries, and partners directly with UNLV’s exceptional talent, transformative research capabilities, and rich pipeline of licensable technologies. Opportunities abound at UNLV for collaborative sponsored research, tailored workforce development programs, robust startup incubation support, and access to patented university technologies poised for commercialization. Discover how partnering with UNLV can propel your organization’s priorities forward through innovative solutions and collaborations. Connect with us at BIO to harness the full potential of our research excellence and vibrant innovation ecosystem. | UNLV, a Carnegie R1 research institution, is a key player in the delegation’s efforts. UNLV emphasizes industry engagement through opportunities for students, strong bio research, innovation, a collaborative research and technology park, and commercialization of life-changing products in fields like life science, physical science, and engineering. UNLV is seeking to connect with BIOtech companies and explore collaboration opportunities.
Repligen
Repligen, a global life sciences company, develops and commercializes innovative bioprocessing technologies that increase efficiencies and flexibility in biotherapeutic manufacturing. As leaders in filtration, chromatography systems, process analytics and fluid management, we are committed to inspiring advances in bioprocessing. We are a trusted partner in the production of monoclonal antibodies, recombinant proteins, vaccines as well as cell and gene therapies. Named one of the fastest growing biotech companies in the USA, the majority of our 18 manufacturing sites are located in the United States (California, Massachusetts, New Jersey, New Hampshire, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. | Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region. | Inspiring advances in bioprocessing, Repligen is a trusted partner in process intensification, pre-packed chromatography and single-use filtration. Focused on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. As the recognized global leader in Protein A manufacturing, Repligen’s Protein A affinity ligands are routinely used to purify most of the world’s monoclonal antibodies.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.
Izon Science
Izon Science is a global leader in nanoparticle characterization, separation, and purification for Exosomes, viruses, and Lipid Nanoparticles (LNPs). Our portfolio includes TRPS and the new NPS (Pulsoid) platforms for precise particle analysis, plus qEV SEC and automated qEV-TFF, Zenco, and DXter systems—supporting workflows from discovery to cGMP-aligned manufacturing. Let’s chat about how we can best support your research. | Izon Science is a global leader in nanoparticle characterization, separation, and purification for Exosomes, viruses, and LNPs. Our portfolio includes TRPS and the new NPS (Pulsoid) platforms for precise particle analysis, plus qEV SEC and automated qEV-TFF, Zenco, and DXter systems—supporting workflows from discovery to cGMP-aligned manufacturing. Let’s chat about how we can best support your research.
Iktos
Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in-silico, optimized to meet all key success criteria of a discovery project. Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery. With over 60 successful projects to date, Iktos supports its clients through software and strategic drug discovery collaborations. Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform. In January 2026, Iktos signed its largest Drug Discovery collaboration to date with Servier, for a total potential deal value of over €1 billion euros. For more information, visit Iktos.ai.
H&T Presspart
H&T Presspart is a world leader and specialist in manufacturing drug delivery devices and pharmaceutical components. With 50 years experience in partnering with the world’s leading pharma companies we have developed a strong reputation for precision and reliability – critically important when patients’ quality of life depends on our products. Our extensive skills and experience cover drug delivery device development and industrialisation and every aspect of high-volume precision deep-drawn manufacturing, injection moulding and high-speed assembly in ISO 7 and ISO 8 cleanrooms.